drugset / Trial / NCT00823979
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a 96 week study to determine if UK- 453,061 in combination with Darunavir /ritonavir and a Nucleos(t)ide Reverse Transcriptase inhibitor is as efficacious, safe and tolerable as etravirine in combination with Darunavir /ritonavir and a Nucleos(t)ide Reverse Transcriptase inhibitor in HIV-1 infected patients who have been previously treated with antiretroviral drugs and have NNRTI resistance mutations.
Timeline
- Start
- 2009-03-25
- Primary completion
- 2012-10-18
- Completion
- 2012-10-18
Outcome
Outcome not reported
Stopped: “See termination reason in detailed description.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etravirine | Small molecule | 200 mg | — |
| Subject | Lersivirine | Small molecule | 750 mg | — |
| Subject | Lersivirine | Small molecule | 1000 mg | — |
Indications
No indication recorded.